Fitch Solutions said on Friday that India will become the largest global center for COVID-19 antiviral generic drug production after the drug controller granted emergency access to several drug companies in the country to manufacture and market generic versions of molnupiravir.
Fitch Solutions said in a report that increased penetration of molnupiravir will keep hospitalizations and deaths in India at a manageable level as Omicron infections rise.
Those authorized by the Drug Controller General of India (DCGI) include Dr Reddy’s Laboratories, Torrent Pharmaceuticals, Cipla, Sun Pharma, Natco Pharma, Viatris, Hetero Drugs and Mankind Pharma.
After authorization, Cipla, Sun Pharma, and Dr Reddy’s Laboratories are set to release Molnupiravir capsules in the coming weeks, and the rest of the companies will follow.
“This will make India the largest global hub for COVID-19 antiviral generic drug production,” it said.
,